Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome
EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the last patient has been …